BIONTECH

ANUAL GENERAL MEETING
2021

June 22, 2021

HARNESSING THE FULL POTENTIAL OF THE IMMUNESYSTEM

ANNUAL GENERAL MEETING 2021

AGENDA

1. Presentation of the adopted annual financial statements, the approved consolidated financial statements, and the combined management report for the Company and the Group as well as the report of the Supervisory Board for the Company, each for the financial year 2020 or as at 31 December 2020, respectively
2. Approval of the actions of the Management Board
3. Approval of the actions of the Supervisory Board
4. Appointment of the auditor for the 2021 financial year
5. Resolution on the revocation of the existing authorized capital and the creation of a new authorized capital (Authorized Capital 2021) against contributions in cash and/or in kind with the possibility of excluding subscription rights and corresponding amendments to the Articles of Association
6. Amendment of the authorization to issue stock options
7. Resolution on the partial revocation and amendment of the current authorization to issue stock options (Stock Option Program 2017/2019) and on the partial revocation of Conditional Capital ESOP 2017/2019; Resolution on the authorization to issue stock options (Stock Option Program 2021) and on the implementation of a new Conditional Capital 2021 and corresponding amendments to the Articles of Association
8. Amendment to the existing authorization to acquire treasury shares and their use, also excluding subscription rights

BIONTECH

ANNUAL GENERAL MEETING 2021

AGENDA (2)

9 Extending the authorization to acquire treasury shares and to use them, also excluding subscription rights

10 Resolution on the approval of the system for the compensation of the members of the Management Board

11 Resolution on the compensation and on the compensation system for the members of the Supervisory Board and an amendment of Sec. 9 para. 6 of the Articles of Association

12 Resolution on the revocation of the resolution of the Company's Annual General Meeting of June 26, 2020 (agenda item 8 letter d)) on the consent to the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company

13 Conclusion of inter-company agreements

a) Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company

b) Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company with BioNTech Manufacturing Marburg GmbH as dependent company

c) Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and reSano GmbH as dependent company

BIONTECH

MANAGEMENT BOARD REPORT

1 **OPERATING DEVELOPMENT 2020 / Q1 2021 and OPERATING OUTLOOK 2021**

Prof. Dr. Ugur Sahin, CEO & Founder

2 **FINANCIAL DEVELOPMENT 2020 / Q1 2021 and FINANCIAL OUTLOOK 2021**

Dr. Sierk Pötting, CFO & COO

2021

Capitalizing on COVID-19 Vaccine Success to Accelerate Execution on our Vision

This slide presentation includes forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including the extent to which a COVID-19 vaccine continues to be necessary in the future; BioNTech's COVID-19 vaccine revenues and net sales, which are subject to numerous estimates as more fully described in our Annual Report on Form 20-F; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the pricing and reimbursement of BioNTech and Pfizer's COVID-19 vaccine and BioNTech's investigational medicines, if approved; the rate and degree of market acceptance of BioNTech and Pfizer's COVID-19 vaccine and BioNTech's investigational medicines, if approved; the initiation, timing, progress, results, and cost of BioNTech's research and development programs and BioNTech's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and BioNTech's research and development programs; the timing of and BioNTech's ability to obtain and maintain regulatory approval for BioNTech's product candidates; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of BioNTech and Pfizer's COVID-19 vaccine, and other products and product candidates developed or manufactured by BioNTech; BioNTech's estimates of its expenses, ongoing losses, future revenue and capital requirements and BioNTech's needs for or ability to obtain additional financing; the development of and projections relating to BioNTech's competitors or its industry; BioNTech's ability to effectively scale its production capabilities and manufacture its products, including BioNTech and Pfizer's COVID-19 vaccine, and BioNTech's product candidates; BioNTech's projected gross margins, expenses and expenditures and tax rate for 2021; BioNTech's target vaccine production for 2021; BioNTech's plans for expansion in South East Asia, including its planned regional headquarters and manufacturing facility in Singapore; and expectations for data announcements with respect to BioNTech's clinical trials. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Annual Report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on March 30, 2021 and in subsequent filings made by BioNTech with the SEC, including the third quarter report, which are available on the SEC's website at www.sec.gov. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof.

BIONTECH

Safety Information

AUTHORIZED USE IN THE U.S.:
The Pfizer-BioNTech COVID19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION:

- Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.
- Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer- BioNTech COVID-19 Vaccine.
- Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/).
- Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.
- Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.
- The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.
- In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%).
- In a clinical study, adverse reactions in adolescents 12 through 15 years of age included pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), injection site redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%)
- Severe allergic reactions, including anaphylaxis, have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials.
- Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 Vaccine.
- Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.
- Data are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion.
- There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series.
- Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The reports should include the words "Pfizer-BioNTech COVID-19 Vaccine EUA" in the description section of the report.
- Vaccination providers should review the Fact Sheet for *Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization.*

Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com.

BIONTECH

Safety Information

AUTHORIZED USE IN THE EU:
COMIRNATY® ▼ (the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorisation by the by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from 12 years of age. The European Medicines Agency's (EMA's) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available.

IMPORTANT SAFETY INFORMATION:
- Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
- Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.
- The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATY® may be lower in immunosuppressed individuals.
- As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine.
- In clinical studies, adverse reactions in participants 16 years of age and older were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.
- The overall safety profile of COMIRNATY® in adolescents 12 to 15 years of age was similar to that seen in participants 16 years of age and older. The most frequent adverse reactions in clinical trial participants 12 to 15 years of age were injection site pain (> 90%), fatigue and headache (> 70%), myalgia and chills (> 40%), arthralgia and pyrexia (> 20%).
- There is limited experience with use of COMIRNATY® in pregnant women. Administration of COMIRNATY® in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and fetus.
- It is unknown whether COMIRNATY® is excreted in human milk.
- Interactions with other medicinal products or concomitant administration of COMIRNATY® with other vaccines has not been studied.
- For complete information on the safety of COMIRNATY® always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website.

The black equilateral triangle denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to EudraVigilance or directly to BioNTech using email medinfo@biontech.de, telephone +49 6131 9084 0, or via the website www.biontech.de

BIONTECH

BioNTech: A Global Immunotherapy Powerhouse

Fully Integrated Structure

- Deep Immunology Expertise
- Broad Suite of Novel Technologies
- Bioinformatics Approach
- In-House Manufacturing
- Commercial Capabilities
- Global Team of 2,000+

A Robust Pipeline of 20+ Candidates

Next-Gen Immunotherapies & Vaccines

Oncology,
Infectious Disease
and Beyond

Potential to Launch Multiple Products in Next 5 Years

Accelerated by Proven Execution, COVID-19 Vaccine Cash Flow & World-Class Collaborations

BIONTECH

COMIRNATY® - First Approved mRNA Vaccine: A Historic 10 Month Achievement with Ongoing Global Impact

- **Just 10 months** to develop a safe and well tolerated vaccine with efficacy of ~95%[1,2]
- **>700 million** doses delivered across **more than 100 countries or regions**[3]
- Fully committed to **supplying COVID-19 vaccine around the world**, to all countries at all income levels
  - Agreement to provide 500 million doses at not-for-profit price to U.S. government for donation to poorest nations
- **Targeting 3 billion** doses manufacturing capacity total for 2021, increasing beyond 3 billion in 2022
- **Rapidly adapting technology**, manufacturing and regulatory processes to respond to emerging variants
- Strong **order book** for 2021, first contracts signed for 2022 and beyond:
  - >1.8 billion doses contracted for 2021 to EU, U.S., Japan, UK and others[4]
  - 900 million doses contracted to EU for 2022-2023 with option for additional 900 million doses

Conditional marketing or emergency use **authorization in >70 countries**:



- Conditional Marketing Authorization[2]
- Approved Emergency Use Authorization / Temporary Use Approval[2]
- Ongoing Phase 2 trial in China

[1] 95% efficacy in preventing symptomatic COVID-19 infections; Polack FP, et al. NEJM 2020, 383:2603-2615
[2] The vaccine is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 12 years of age and older.
[3] As of June 10, 2021
[4] As of May 10, 2021.

BIONTECH

BioNTech Transformed in 2020 and 2021

First Product Launch

BNT162b2 launched globally

mRNA established as **new drug class**

Commercial

Established first sales force

Successful commercial launch in Germany with **BioNTech sales team**

Manufacturing

Acquired Marburg commercial-scale GMP facility

Own mRNA manufacturing network with up to **1 billion dose** annual capacity

Robust Pipeline

Broadened clinical-stage pipeline to 16 ongoing clinical trials

3 cancer immunotherapies to enter **Phase-2 trials** in 2021 with registrational potential

Technology Diversity

Addressing multiple disease areas with synergistic therapeutic modalities

14 clinical stage **product candidates** across **4 drug classes**

Global Footprint

Grew to >2,000 employees with >600 in R&D

Expanded sites in Germany, established U.S. HQ in Cambridge, MA[1] and Southeast Asia regional headquarters in Singapore

[1] Acquisition of Neon Therapeutics

Key Insights from 2020 Demonstrate BioNTech's Disruptive Potential

Our mRNA Technology has Potential to Address Major Global Health Challenges

- First COVID-19 mRNA vaccine highlights promise of vaccine platform
- New products can be improved through rapid iteration
- Broad toolbox of mRNA technologies established that underpin a diverse range of new prophylactic and therapeutic platforms

BioNTech is Positioned to Lead

- Vast IP portfolio
- More than a decade of accumulated know-how in the field
- Increasing investment in integrated infrastructure and R&D to accelerate pipeline and stay at forefront

Drug Development Can be Faster

- Apply capabilities developed during "Project Lightspeed" to rapidly advance other innovative medicines to the market

Our Model is Powerful

- Deep focus on innovation plus synergistic blue-chip collaborations enables market-leading position while expanding internal capabilities

Validation of BioNTech mRNA Technology Unlocks New Therapeutic Universe

Our mRNA technology, as a new drug class, underpins multiple therapeutic platforms with potential to:

1. Address Broad Disease Areas

- Infectious disease
- Oncology
- Allergy
- Autoimmune and inflammatory disease
- Regenerative medicine

2. Replace Traditional Modalities

- mRNA infectious disease vaccines
- mRNA cancer vaccines
- CAR-T cell amplifying mRNA vaccine
- Systemic mRNA encoded immuno-therapies

BioNTech aims to fully exploit and industrialize its sophisticated expertise, technology and in-house manufacturing

BIONTECH

2021 Strategic Priorities: Reinvest Capital to Drive Innovation

Increase Global Footprint

- New regional headquarters planned in Singapore
- Commercial subsidiaries established in Germany and Turkey
- Offices established in the United States

Expand Integrated Infrastructure

- Continue investment in innovation to support future product launches
- Invest in clinical, commercial, manufacturing, and digital capabilities
- Attract and retain top talent

Rapidly Advance Pipeline

- 3 potentially registrational phase 2 trials initiating this year
- Advance innovations into first-in-human studies in oncology and infectious disease
- Strategic in-licensing to complement internal R&D

Vaccine revenue provides significant working capital to build long-term value for patients, shareholders and society

BIONTECH

Six Key Levers to Expand COVID-19 Vaccine Reach as Market Leaders

Increased Manufacturing Capacity

Expansive Global Clinical Program Supports Label Expansion to Additional Populations

Regulatory Advancement Across all Geographies

Addressing Waning Immunity with Revaccination

Optimize Formulations to Further Simplify Access Worldwide

Establish Development, Manufacturing and Regulatory "Blueprint" for Variants

Continuous strong growth in order book secures market leading position

BIONTECH

Advancement of Additional Infectious Disease Programs in 2020-2021

De-risked Pipeline in Infectious Disease

- Preclinical development of multiple product candidates for HIV and tuberculosis in collaboration with the Bill & Melinda Gates Foundation

- Preclinical development of up to 10 mRNA vaccine candidates for various infectious diseases with high unmet medical need as part of University of Pennsylvania collaboration

- BNT161 influenza vaccine first in human study planned to initiate in Q3 2021
  - Eligible for milestone payments and royalties through Pfizer licensing agreement

BIONTECH

Oncology: Tackling Multiple Diseases with Different Therapeutic Modalities

mRNA Cancer Vaccines

iNeST and FixVac

- Multi-specificity, multi-valency, high (neo)antigen specific T cell responses with unprecedented potency
- 2 ongoing Phase 2 randomized trials (iNeST and FixVac)

Next Generation Immunomodulators

Bispecifics

- Next-generation checkpoint inhibitors to address a broad range of cancers
- Ongoing Phase 1/2 trials of 2 bi-specific antibodies



Targeting Cancer + Immunomodulation

- Next Gen CAR-T Cell Therapy
- Neoantigen-based T Cell Therapy

- Phase 1 FIH trials started in Feb. and Apr 2021.

Cell Therapies

Targeted Cancer Antibodies

- CA19-9 antibody in 1L pancreatic cancer
- Ongoing Phase 1/2 trial

Antibodies

TLR-7 Agonist

- Potently modulates innate immunity
- Potential for combination with other IO agents
- Ongoing Phase 1 trial

Small Molecule Immunomodulators

Ribocytokines

- mRNA encoded cytokines with a prolonged T1/2 and improved safety profile
- Amplify vaccines and CPIs
- Phase 1 FIH trial started in Feb. 2021

Engineered Cytokines

Multiple blockbuster opportunities and synergistic combinations

CA 19-9: Cancer antigen 19-9; IO, Immuno-oncology; CPI, Check-point Inhibitor; FIH, First-in-human; T1/2, half-life

Multiple Oncology Trials with Registrational Potential Starting in 2021

BNT 111: Phase 2 FPD in June

Snapshot: Advanced Oncology Pipeline Programs

Drug Class	Platform	Product Candidate	Indication (Targets)	Preclinical	Phase 1	Phase 2
mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	advanced melanoma			
		BNT113	HPV16+ head and neck cancer			
	iNeST (patient specific cancer antigen therapy)	autogene cevumeran (BNT122)	1L melanoma			
			adjuvant colorectal cancer			
Antibodies	Next-Gen Checkpoint Immunomodulators	GEN1046 (BNT311)	solid tumors (PD-L1×4-1BB)			
		GEN1042 (BNT312)	solid tumors (CD40×4-1BB)			

Near-Term Milestones

- **BNT111: Phase 2 FPD in June 2021**
- **BNT113: Phase 2 to start in 1H 2021**
- **BNT122: Phase 2 to start in 2H 2021 (adjuvant CRC)**
- **BNT311: Data update in 2H 2021**
- **BNT312: Data update in 2H 2021**

Planned randomized trial start in 2021
FPD, First Patient Dosed; 1L, First-Line; CRC, Colorectal Cancer

BIONTECH

Next Wave Oncology Advancing Innovation Beyond Current Boundaries

CARVac
CAR-T cell amplifying mRNA therapy for solid tumors[1]



- **BNT211 (CLDN 6 CAR)**
  Next generation CAR-T targeting CLDN6 with CARVac

Wholly owned: ✓

FIH start: **FPD Feb. 2021**

NEOSTIM T cell therapy
Individualized Neoantigen specific T cell therapy



- **BNT221**
  PBMC derived ex vivo T cell therapy

Wholly owned: ✓

FIH start: **FPD Apr. 2021**

RiboCytokines
mRNA encoded Cytokines



- **BNT151**
  (modified IL-2)
- **BNT152 + BNT153**
  (IL-2/IL-7)

Wholly owned: ✓

FIH start: **BNT151: FPD Feb. 2021**

RiboMabs[2]
mRNA encoded Antibodies



- **BNT141**
  (undisclosed)
- **BNT142**
  (CD3xCLDN6)

Wholly owned: ✓

FIH start: **2H 2021**

FPD, First Patient Dosed; CLDN6, Claudin-6, CAR-T Cells, Chimeric Antigen Receptor T Cells; IL-2, Interleukin 2; IL-7, Interleukin 7; PBMC, Peripheral Blood Mononuclear Cells; FIH, First in Human

[1] Reinhard K, et al. Cancer Immunotherapy 2020; 367:446-453; [2] Stadler et al, Oncoimmunology 2018

BIONTECH

Significant Pipeline Milestones Expected in 2021; Multiple Already Achieved

5+ Trial Updates

- **BNT162b2:** Multiple updates
- **BNT311:** Bi-specific CPI: PD-L1 x 4-1BB in solid tumors
- **BNT312:** Bi-specific CPI: CD40 x 4-1BB in solid tumors
- **BNT211:** CLDN-6 CAR-T + CARVac in solid tumors
- **BNT411:** TLR-7 agonist +/- CPI in solid tumors

3 Randomized Phase 2 Trial Starts

- **BNT111:** FixVac + CPI in refractory melanoma
- **BNT113:** FixVac HPV16+ + CPI in 1L HNSCC
- **BNT122:** iNeST (autogene cevumeran) + CPI in adjuvant mCRC

7 First-in-human Phase 1 Trial Starts

- **BNT211:** CLDN-6 CAR-T + CARVac in solid tumors
- **BNT151:** Ribocytokine (modified IL-2)
- **BNT221:** NEOSTIM individualized neoantigen-T cell therapy in melanoma
- **BNT152+153:** RiboCytokine IL-2 / IL-7 combo in solid tumors
- **BNT141**: RiboMab (undisclosed)
- **BNT142:** RiboMab bi-specific CPI in solid tumors (CD3xCLDN6)
- **BNT161:** Influenza vaccine

CLDN6, Claudin-6, CAR-T Cells, Chimeric Antigen Receptor T Cells; IL-2, Interleukin 2; IL-7, Interleukin 7;
CPI, Check-Point Inhibitor; HNSCC, Head and Neck Squamous Cell Carcinoma; mCRC, Metastatic Colorectal Cancer

Well Positioned for Future Success as We Execute on Our Strategy

Our Vision: Harnessing the immune system's full potential to fight human disease.

Robust pipeline

Technologies with best-in-class potential

Global team with deep expertise

World-class collaborators

Strong financial position to support company advancement

BIONTECH

MANAGEMENT BOARD REPORT

1 OPERATING DEVELOPMENT 2020 / Q1 2021 and OPERATING OUTLOOK 2021

Prof. Dr. Ugur Sahin, CEO & Founder

2 **FINANCIAL DEVELOPMENT 2020 / Q1 2021 and FINANCIAL OUTLOOK 2021**

Dr. Sierk Pötting, CFO & COO

BIONTECH

2020 Financial Year Results

(in millions, except per share and shares issued data)[1]	BioNTech Group (IFRS)		BioNTech SE (HGB)	
	Years ended December 31,		Years ended December 31,	
	2020	2019	2020	2019
Results of Operations (condensed)				
• Revenues	€482.3	€108.6	€362.8	€31.2
• Cost of sales	€(59.3)	€(17.4)	€(15.6)	€(0.0)
• Research and development expenses	€(645.0)	€(226.5)	€(405.3)	€(87.4)
• General and administrative expenses	€(94.0)	€(45.5)	€(107.8)	€(53.8)
• Income taxes	€161.0	€0.3	-	€0.3
Profit / (loss) for the period	**€15.2**	**€(179.2)**	**€(128.9)**	**€(194.5)**
Basic and diluted profit / (loss) for the period per share	**€0.06**	**€(0.85)**		
	December 31, 2020	**December 31, 2019**	**December 31, 2020**	**December 31, 2019**
Financial Position and Net Assets (condensed)				
• Total equity / thereof accumulated losses[2]	€1,371.8 / €(409.6)	€493.5 / €(424.8)	€1,374.5 / €(512.9)	€588.7 / €(384.0)
• Ordinary shares issued (thereof held in treasury)	246,310,081 (4,789,016)	232,304,250 (5,524,506)	246,310,081 (4,789,016)	232,304,250 (5,524,506)
• Cash and cash equivalents	€1,210.2	€519.1	€976.3	€366.3

1 Numbers have been rounded and may have been adjusted in the table context.
2 Including profit / (loss) for the period.

2020 COVID-19 Vaccine Deliveries Drove Revenue Growth

Commercial revenues – newly identified revenue streams



- Share of gross profit from COVID-19 vaccine sales in the Pfizer territory (net position)[1]
- Sales to our collaboration partner of products manufactured by us
- Direct COVID-19 vaccine sales to customers in our territory Germany
- Other sales (mainly includes JPT and IMFS business)

[1] Represents estimated figure based on preliminary data shared between Pfizer and us. Changes in our share of the collaboration partner's gross profit are recognized prospectively.

2021 Q1 Financial Update

(in millions, except per share and shares issued data)[1]	BioNTech Group (IFRS)	
	Three months ended March 31,	
	2021	2020
Results of Operations (condensed)		
• Revenues	€2,048.4	€27.7
• Cost of sales	€(233.1)	€(5.9)
• Research and development expenses	€(216.2)	€(65.1)
• General and administrative expenses	€(38.9)	€(15.8)
• Income taxes	€(514.2)	-
Profit / (loss) for the period	**€1,128.1**	**€(53.4)**
Basic profit / (loss) for the period per share	**€4.64**	**€(0.24)**
Diluted profit / (loss) for the period per share	**€4.39**	**€(0.24)**
	March 31, 2021	**December 31, 2020**
Financial Position and Net Assets (condensed)		
• Ordinary shares issued (thereof held in treasury)	246,310,081 (4,789,016)	246,310,081 (4,789,016)
• Cash and cash equivalents	€891.5	€1,210.2

[1] Numbers have been rounded and may have been adjusted in the table context. Unaudited figures are derived from our interim unaudited condensed consolidated financial statements which were filed with the SEC in our Quarterly Report on Form 6-K on May 10, 2021.

2021 Financial Outlook

Signed COVID-19 Vaccine Order Book

- Estimated COVID-19 vaccine revenues to BioNTech upon delivery of signed supply contracts as of May 4, 2021 (~1.8 billion doses): ~€12.4 billion

Planned Full Year 2021 Expenses and Capex

- Research and development expenses: **€750 million – €850 million**
- Sales and marketing as well as general and administrative expenses: **Up to €200 million**
- Capital expenditures: **€175 million – €225 million**
- *Ranges reflect current base case projections*
- *Ramp-up of R&D investment in H2 2021 and beyond planned to broaden and accelerate pipeline development*

Estimated Full Year 2021 Tax Assumptions

- German tax group income tax rate: **~31%**

2020 Financial Year Capital Transactions

	Number of ordinary shares / ADS issued	Subscription price	Gross proceeds
Capital Increases from Authorized Capital with partial Exclusion of Subscription Rights			
• Fosun Pharma	1,580,777	€28.83[1]	€45.6 million[1]
• Pfizer	2,377,446	€43.70[1]	€103.9 million[1]
• Neon Therapeutics	1,935,488	contribution in kind	contribution in kind
• June 2020 Private Placement	2,595,996	€47.71	€123.9 million
• Global Offering[2]	5,516,124	€79.09[1]	€436.3 million[1]
Total number of ordinary shares / ADS issued from authorized capital with partial exclusion of subscription rights	**14,005,831**		
Utilization of Treasury Shares			
• At-The-Market Offering Program	735,490[3]	€104.07[1]	€76.5 million[1]
Total number of treasury shares disposed	**735,490**		

1 Ordinary shares / ADS have been issued in US-Dollar; amounts have been translated into Euro using the exchange rates published by the German Federal Bank (Deutsche Bundesbank) as of the date of transaction. Rounding differences may occur.

2 Includes the "Underwritten Offering" and the "Rights Offering", which were entered into consecutively. The exact terms of the "Global Offering" were published in accordance with applicable laws in a separate prospectus.

3 Represents utilization of ordinary shares that had previously been held in treasury.

BIONTECH

Sustainability: At Top 10% Of Industry With ESG Prime Rating[1]

Access to Medicine (ATM)

BioNTech strives for equitable and affordable access to COVID-19 vaccines for all countries around the world.

Environmental & Climate Protection

We are committed to having a positive and sustainable impact globally and to become climate neutral by 2030 at the latest. Our environmental management system is being further strengthened.

Attractive Employer

With lived diversity and a commitment to equal opportunity and non-discrimination, we innovatively develop our employees while ensuring high occupational health and safety standards.

- **60+ nations**
- **45% of top management are women**

Responsible Governance

We act ethically and responsibly and take all stakeholder interests into account.

- **Strong patient safety and privacy focus**
- **Human Rights Approach based on Supplier Code of Conduct**

[1] "Prime" rating at the end of April 2021 by ISS ESG, one of the world's leading sustainability rating agencies.

An der Goldgrube 12
55131 Mainz
Germany

M: **investors@biontech.de**

© Copyright BioNTech SE 2021. All Rights Reserved.